GE Healthcare
Imaging, monitoring, and healthcare IT solutions
Director of ASL Central & Pediatric MR
Relocation assistance is provided.
About the job
- A Ph.D. in Physics, Biomedical Engineering, Electrical Engineering, or a related discipline is required.
- At least 7 years of experience in MR imaging research or a closely related healthcare field is required.
- At least 5 years of experience in industrial research and development, product development, or similar roles is required.
- A strong technical foundation in MR science is required.
- Strong oral and written communication skills in English are required.
- Experience serving as a project manager, team lead, or section manager is required.
- The ability to work effectively with diverse stakeholders is required.
- The ability to operate within matrixed and global environments and influence across teams is required.
- Experience leading complex, cross-functional scientific or research initiatives is required.
- The ability to influence, collaborate, and build relationships across a global organization is required.
- Serve as the primary GE HealthCare leader for ASL Central, guiding its strategy, operations, and collaborative initiatives.
- Lead the build-out and operational launch of the ASL Central facility in Cincinnati, including coordination with internal teams and external partners.
- Coordinate and prioritize the activities of GE HealthCare teams supporting ASL Central and work with local partners to ensure operational success.
- Operate effectively in a matrixed global organization and influence stakeholders across functions without direct authority.
- Drive site strategy and execution, including research prioritization, collaboration selection, and operational success metrics.
- Identify, nurture, and expand research and clinical collaborations, particularly with the University of Cincinnati and Cincinnati Children's Medical Center.
- Define GE HealthCare's roadmap and development strategy for pediatric MR while aligning with the broader MR strategy.
- Advance pediatric MR optimization by addressing the unique challenges of imaging children and translating innovations into clinical practice.
- Drive innovation and scientific contributions, including new MR techniques, applications, and peer-reviewed publications.
- Represent GE HealthCare in the pediatric MR community by engaging with customers, research collaborators, external partners, and professional societies.
- Stay informed of emerging trends in pediatric imaging and anticipate clinical needs that will shape future innovations.
- Support pediatric customer satisfaction efforts and assist with installed-base issues to ensure a strong customer experience.
- Partner with segment leaders, marketing teams, and engineering groups to translate new MR research into viable product solutions.
- Collaborate with GE HealthCare marketing to create educational and promotional materials supporting pediatric MR solutions.
- A proven record of innovation in MR physics, including pulse sequence development, reconstruction methods, or new MR imaging applications, is preferred.
- Experience or interest in pediatric imaging and MR optimization for children is preferred.
- An inclusive leadership style with the ability to motivate, engage, and develop team members is preferred.
- People-leader and/or team-leadership experience is preferred.
- Experience supporting or conducting clinical research studies or clinical trials is preferred.
- Prior experience with GE HealthCare MR systems is preferred.
About the company
GE Healthcare Systems provides medical technologies and digital infrastructure to improve diagnosis, treatment, and monitoring of patients. Its products include imaging systems, mobile diagnostic devices, patient monitoring tools, and healthcare IT software that work together as hardware, software, and services to support hospitals, clinics, and researchers. The company differentiates itself with a large, integrated ecosystem, strong focus on AI analytics, and a global service network backed by substantial R&D investment. Its goal is to improve patient outcomes and the efficiency of healthcare delivery by enabling accurate diagnoses, effective treatments, and scaled operations.
Company Size
1-10
Company Stage
IPO
Headquarters
Chicago, Illinois
Founded
1892
Get referred to GE Healthcare
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 orders rose 11.1% and backlog hit a record $23.9 billion.
- September 2026 brought FDA MRI clearances and CE marks for Photonova Spectra.
- CareIntellect for Operations launched with Duke and Queen's Health to predict bottlenecks 72 hours ahead.
What critics are saying
- Patient Care Solutions revenue fell 13.5% in Q2 2026; management still reviews a sale.
- FDA classified an AW Server recall on June 24, 2026; wrong-patient reads threaten trust.
- Aurora plant union filed NLRB charges in 2026, while shareholder fraud probes expanded September 2026.
What makes GE Healthcare unique
- GE HealthCare spans MRI, CT, ultrasound, and radiopharmaceutical imaging across hospitals and clinics.
- Photonova Spectra and SIGNA clearances show deep FDA-regulated imaging engineering and software integration.
- CareIntellect, MIM Anyware, and AI-assisted ultrasound deepen workflow lock-in across clinical teams.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Tuition Reimbursement
Relocation Assistance
Company News
GE HealthCare has launched CareIntellect for Operations, an AI-powered software application that helps health systems forecast capacity constraints up to 72 hours ahead. The solution analyses hundreds of patient and operational data points to predict bottlenecks and recommend actions to optimise capacity and throughput. The Queen's Health Systems and Duke Health will be the first to implement the application. It uses two proprietary AI models: the Pressure Forecast model, which predicts resource constraints across hospitals and departments, and the Estimated Day of Discharge model, which predicts when patients will be discharged. The tool addresses operational challenges as US inpatient volumes rose 5.3% in 2025, requiring health systems to manage increased demand whilst facing staffing shortages and rising costs.
GE HealthCare has received CE mark approval for its Photonova Spectra photon-counting computed tomography system, enabling commercial sales in markets recognising CE marking. The clearance follows US Food and Drug Administration approval and Japanese regulatory clearance in March 2026. The system uses GE HealthCare's Deep Silicon detector technology to deliver ultra-high definition spectral and spatial imaging. It processes data volumes up to 50 times greater than conventional CT systems, utilising Nvidia's accelerated computing platform. Clinical collaborations are underway at UZ Brussel in Belgium and Rigshospitalet in Denmark to evaluate the system across cardiology, neurology, oncology and musculoskeletal imaging. The CE mark follows more than $5 billion in innovation investment by GE HealthCare.
Vertex Pharmaceuticals has emerged as a standout S&P 500 stock, according to StockStory's analysis. The company, which focuses on developing transformative medicines for serious diseases including cystic fibrosis and sickle cell disease, boasts a market capitalisation of $137.3 billion. Meanwhile, StockStory recommends avoiding two large-cap stocks. GE HealthCare, spun off from General Electric in 2023, faces concerns over stagnant organic revenue growth and declining operating margins. The medical equipment provider has a market cap of $32.4 billion. Wells Fargo also made the avoid list. The diversified financial services company, with a $262.2 billion market cap, has seen its net interest margin shrink by 33.6 basis points over two years, suggesting increased competition or declining loan profitability.
GE HealthCare has introduced three new cardiovascular ultrasound systems to its Vivid portfolio: Vivid Explorer 1, Vivid Advanced 1, and Vivid Focus 1. The systems were unveiled at the European Society of Cardiology Congress 2026 in Munich, Germany. Each system targets different clinical settings whilst sharing a common technology foundation with the ultra-premium Vivid Pioneer. Vivid Explorer is designed for high-volume echo labs, Vivid Advanced for mid-size hospitals and cardiology practices, and Vivid Focus for everyday cardiac imaging. All three systems use cSound imaging technology and include AI-enabled automation tools to streamline echo workflows. The systems have received CE Mark approval but are awaiting US FDA 510(k) clearance and are not yet available for sale in the United States.
GE HealthCare has launched Invenia ABUS Prime and ABUS StreamVue, expanding its breast imaging portfolio with solutions for supplemental screening in women with dense breasts. The Invenia ABUS Prime system has been installed at BeSound in Los Angeles, marking one of the first US installations. ABUS StreamVue is a browser-based reading solution enabling remote exam review across imaging networks. The system received FDA 510(k) clearance and CE Marking. Studies show 40% of women have dense breasts, carrying four to six times higher breast cancer risk. Research indicates mammography may miss one-third of cancers in dense breasts. Invenia ABUS Prime features AI-enabled tools including Scan Quality Assessment and can increase scan speed by up to 40%. The AI Assistant has demonstrated a 33% reduction in reading time.